Energenesis Biomedical Co

Energenesis Biomedical Co Current Assets

The Current Assets of Energenesis Biomedical Co (6657.TW) as of Nov 3, 2026 is 860.37 M TWD. In the previous year, Current Assets was 689.30 M TWD — a change of 24.82% (higher).

Current Assets

860.37 MTWD

YoY

24.82%

Last updated:

Current Assets of Energenesis Biomedical Co is 2025 860.37 M TWD. Current Assets of Energenesis Biomedical Co was 2024 689.30 M TWD. It decreases by 24.82% higher compared to the previous year.

The Energenesis Biomedical Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
342.50 M TWD
Jan 1, 2019
660.94 M TWD
Jan 1, 2020
554.96 M TWD
Jan 1, 2021
740.38 M TWD
Jan 1, 2022
503.82 M TWD
Jan 1, 2023
720.78 M TWD
Jan 1, 2024
689.30 M TWD
Jan 1, 2025
860.37 M TWD
The Energenesis Biomedical Co Current Assets history
YEARCurrent AssetsYoY
860.37 MTWD+24.82%
689.30 MTWD-4.37%
720.78 MTWD+43.06%
503.82 MTWD-31.95%
740.38 MTWD+33.41%
554.96 MTWD-16.04%
660.94 MTWD+92.98%
342.50 MTWD+155.98%
133.80 MTWD+44.65%
92.50 MTWD+98.92%
46.50 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Energenesis Biomedical Co Stock analysis

What does Energenesis Biomedical Co do? Energenesis Biomedical Co., Ltd. develops new drugs, focusing on experimental service analysis and reagent sales as its main products. The company's primary new drugs include ENERGI-F703 for diabetic foot ulcers, ENERGI-F701 for abnormal alopecia, ENERGI-F711 for burns, and ENERGI-F706 for cachexia. These products target medical professionals and healthcare institutions seeking innovative treatments for specific conditions. The firm generates revenue through the sale of experimental services and reagents, as well as the commercialization of its drug pipeline. Energenesis Biomedical's product portfolio is centered around four key drug candidates, each addressing distinct medical needs. ENERGI-F703 addresses diabetic foot ulcers, a common complication in diabetes management, while ENERGI-F701 targets abnormal alopecia, a condition affecting hair growth. ENERGI-F711 is designed for burn treatment, and ENERGI-F706 focuses on cachexia, a wasting syndrome often associated with chronic diseases. These drugs are developed for direct sales to healthcare providers and institutions. The company's revenue streams are derived from two main areas: the sale of experimental service analysis and reagent products, alongside the future commercialization of its drug candidates. Healthcare institutions and medical professionals are the primary buyers of these products, seeking advanced solutions for diabetic foot ulcers, alopecia, burns, and cachexia. Energenesis Biomedical's business model relies on the successful development and market entry of its drug pipeline to generate sustained revenue. Energenesis Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Energenesis Biomedical Co stock

Current Assets of Energenesis Biomedical Co is 860.37 M TWD in 2025.

Current Assets of Energenesis Biomedical Co changed from 689.30 M TWD to 860.37 M TWD, representing a 24.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Energenesis Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Energenesis Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Energenesis Biomedical Co

All Key Metrics — Energenesis Biomedical Co